Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract CancerDo‐Youn Oh, Juan W. Valle, Aiwu Ruth He et al.|NEJM Evidence|2022Cited by 1.1k
Trans-ancestry mutational landscape of hepatocellular carcinoma genomesYasushi Totoki, Tatsuhiro Shibata, Kenji Tatsuno et al.|Nature Genetics|2014Cited by 780
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in JapanTakuji Okusaka, Y Nimura, Kohei Nakachi et al.|British Journal of Cancer|2010Cited by 749
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trialMasatoshi Kudo, Yasuaki Arai, Kazuomi Ueshima et al.|Gut|2019Cited by 720
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST StudyHideki Ueno, Masao Tanaka, Tatsuya Ioka et al.|Journal of Clinical Oncology|2013Cited by 632